Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292232 | 0.85 | KDM4E (0.56) | KDM4EGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6750341 | 0.82 | KDM4E (0.53) | KDM4EGAAALDH1A1POLBHPGD | |
| SCHEMBL27459826 | 0.78 | HPGD (0.55) | KDM4EGAAALDH1A1POLBHPGD | |
| SCHEMBL79802 | 0.77 | KDM4E (1.00) | KDM4EGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3293384 | 0.76 | KDM4E (0.70) | KDM4EGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1600584 | 0.76 | KDM4E (0.76) | KDM4EGAAALDH1A1POLBSMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL27471544 | 0.76 | KDM4E (0.96) | KDM4EGAAALDH1A1POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28063235 | 0.75 | KDM4E (0.73) | KDM4EGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3070293 | 0.75 | KDM4E (0.67) | KDM4EGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL28087177 | 0.74 | ALDH1A1 (0.54) | KDM4EGAAALDH1A1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | BAYER HEALTHCARE AG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1414788-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003089404-A1 | NAPHTHALENE AMIDES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030199578-A1 | Naphthalene amides as potassium channel openers | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
| WO-2003014064-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199578-A1 | Naphthalene amides as potassium channel openers | KCNJ2, KCNN2, KCNJ1 | KDM4E 1005/4885GAA 3159/4885ALDH1A1 1856/4885 |
| US-20040259875-A1 | Amine derivatives | AVPR1A, GRIN1, OPRL1 | KDM4E 3941/4885GAA 4358/4885ALDH1A1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.